Analysis of Treatment Tolerance and Factors Associated with Overall Survival in Elderly Patients with Glioblastoma

Autor: Zhaoping Su, Guidong Song, Shuyu Hao, Nan Ji, Peng Zhang, Jiangfei Wang, Zhixian Gao, Chaocai Zhang, Yajie Li, Jian Xie, Lanbing Yu, Xingchao Wang
Rok vydání: 2016
Předmět:
Male
Oncology
medicine.medical_specialty
medicine.medical_treatment
Population
Neurosurgical Procedures
03 medical and health sciences
0302 clinical medicine
Internal medicine
Temozolomide
medicine
Humans
Karnofsky Performance Status
education
Antineoplastic Agents
Alkylating
Aged
Proportional Hazards Models
Retrospective Studies
Aged
80 and over
Univariate analysis
education.field_of_study
Brain Neoplasms
business.industry
Hazard ratio
Retrospective cohort study
Chemoradiotherapy
Adjuvant
Middle Aged
Prognosis
Combined Modality Therapy
Confidence interval
Surgery
Dacarbazine
Survival Rate
Radiation therapy
Chemotherapy
Adjuvant
030220 oncology & carcinogenesis
Multivariate Analysis
Female
Radiotherapy
Adjuvant
Neurology (clinical)
Neurosurgery
Tumor Suppressor Protein p53
Glioblastoma
business
030217 neurology & neurosurgery
medicine.drug
Zdroj: World Neurosurgery. 95:77-84
ISSN: 1878-8750
Popis: As the population ages, the proportion of elderly patients with glioblastomas has increased. Recently, many researchers have focused on the treatments available to and prognoses in elderly patients with glioblastomas.We conducted a retrospective study of glioblastoma patients aged 60 years old or older who were treated at the Neurosurgery Center at Beijing Tiantan Hospital from 2012 to 2014. Their clinical features, immunohistochemical characteristics, treatments, and outcomes were evaluated to determine treatment tolerance and identify prognostic factors.Among the 70 included patients, the median survival time was 15 months. In the univariate analysis, patients who underwent a gross total resection had longer overall survival times than patients who had a subtotal resection (P0.05), and patients who received postoperative adjuvant therapy had longer overall survival times than those with no postoperative adjuvant therapy (P0.05). The expression of the p53 protein significantly affected overall survival. Patients with low p53 protein expression had a median survival of 17 months, whereas those who had high p53 protein expression had a median survival of 11.50 months (P0.05). Undergoing a gross total resection, receiving postoperative adjuvant therapy and having low p53 protein expression were factors that independently contributed to longer overall survival times in multivariate analysis.Maximal safe surgical resection followed by radiotherapy with concurrent and adjuvant temozolomide significantly prolonged overall survival times and was well tolerated in elderly patients with glioblastomas. In addition, low p53 protein expression was a significant favorable prognostic indicator in this population.
Databáze: OpenAIRE
Externí odkaz: